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Abstract 
Background  Female patients with atrial fibrillation (AF) experience increased risk of thromboembolism compared to males, an 
observation that is reflected by its inclusion in the CHA2DS2VASc score. New onset AF (often associated with tachycardia) also confers 
upon patients increased thromboembolic risk. The mechanisms underlying this risk are uncertain, but new onset AF is associated with 
profound impairment of platelet nitric oxide (NO) signalling. Given that cardiovascular responses to catecholamines are gender-dependent, 
and that the presence of tachycardia in new onset AF may represent a response to catecholaminergic stimulation, we explored the potential 
impact of gender and tachycardia on platelet aggregation and NO signalling. Methods  Interactions were sought in 87 AF patients between 
the extent of adenosine diphosphate (ADP)-induced platelet aggregation, the anti-aggregatory effects of the NO donor, sodium nitroprusside, 
gender, and admission heart rate. The potential impact of platelet expression of thioredoxin-interacting protein (Txnip) was also evaluated. 
Results  Analysis of covariance confirmed the presence of physiological antagonism between platelet ADP and NO responses [F (1, 74) = 
12.212, P < 0.01], while female sex correlated with impaired NO responses independent of platelet aggregability [F (2, 74) = 8.313, P < 
0.01]. Admission heart rate correlated directly with platelet aggregation (r = 0.235, P < 0.05), and inversely with NO response (r = 0.331, P 
< 0.01). Txnip expression varied neither with gender nor with heart rate. Conclusions  These results indicate that gender and heart rate are 
independent determinants of platelet function. Prospective studies of the putative benefit of reversal of tachycardia on restoration of normal 
platelet function are therefore a priority. 
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1  Introduction 
Clinical factors associated with increased thromboem-
bolic risk in atrial fibrillation (AF) have been identified 
epidemiologically and formalised into stroke risk algori-
thm.[1,2] However, the physiological bases underlying these 
categories of risk are as yet incompletely understood. In 
particular, while platelet hyperaggregability has been 
observed in the context of AF,[3,4] its potential role in 
determining thromboembolic risk remains unclear, studies 
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have so far failed to establish a correlation between platelet 
reactivity and clinical scores of thromboembolic risk.  
Among factors which have been shown to modulate pla-
telet aggregability are the interactions between ambient pro- 
aggregatory stimuli (such as plasma catecholamine concen-
trations),[5] and anti-aggregatory autocoids such as nitric 
oxide (NO). We have previously shown that the inhibitory 
response of platelets to NO varies widely in patients with 
AF,[6] and is particularly impaired in ‘new onset’ AF. Me-
chanisms to account for this were not fully explored, 
although theoretically, sources of impaired response to NO 
might include increased reactive oxygen species (ROS) 
generation,[7] and/or oxidation/depletion of the haeme com-
ponent of soluble guanylate cyclase (sGC) (see Chirkov and 
Horowitz[8] for review). 
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Recent onset AF is often associated with relatively rapid 
ventricular response,[9] symptomatic of acutely increased 
sympathetic stimulation. In this context, elevated plasma 
catecholamine concentrations could contribute to platelet 
hyper-reactivity through direct pro-aggregatory effects,[5] as 
well as through increased ROS generation,[1012] and resultant 
scavenging of NO. Pro-inflammatory effects of catechola-
mine release measured in myocardium occur predominantly 
in ageing females,[13] hence there may in theory be gender- 
specifc aspects to this phenomenon. 
Another possible mechanism accounting for the inter-
action between heart rate and impaired NO response in new 
onset AF is the stimulation of inflammation. This could, for 
example, occur via oxidant-stimulated increased expression 
of the pro-inflammatory protein, thioredoxin-interacting 
protein (Txnip, see Chong, et al.[14] for review), which 
appears to suppress NO responses.[15]  
We have therefore performed further evaluations of the 
physiological data from Standard vs. Atrial Fibrillation spE-
cific managemenT studY (SAFETY) in order to delineate 
potential mechanisms underlying the interactions of tachy-
cardia with impaired platelet NO signalling. 
2  Methods 
2.1  Patient selection 
The investigation was conducted as a single centre 
mechanistic sub-study of the SAFETY, an investigation of 
non-pharmacological management strategies in patients 
hospitalized with AF.[16,17] Patients were considered for in-
clusion if they were admitted to hospital due to AF. Exclu-
sion criteria for SAFETY were age < 45 years, primary di-
agnosis of valvular heart disease, scheduled catheter abla-
tion of AF, pre-existing NYHA class III–IV heart failure 
with a documented left ventricular ejection fraction (LVEF) 
< 45%, alcohol-induced AF and terminal illness requiring 
palliative care. Patients receiving P2Y12 receptor antagonists 
were also excluded from the current sub-study because of 
potential impact of such agents on capacity to measure 
platelet response to NO. The study was approved by the 
institutional Ethics of Human Research Committee. Written 
informed consent was obtained in all cases. 
2.2  Clinical data 
All patients underwent standardized clinical assessment 
and routine biochemical investigation. Additional cardiac 
investigations were resting ECG (which was used for meas-
ures of admission heart rate) and transthoracic echocardi-
ography: LVEF was calculated from biplane images using 
Simpson’s method.[18]  
2.3  Platelet aggregometry  
Platelet aggregometry was performed using whole blood 
impedance aggregometry as previously described.[19] Briefly, 
venous blood was collected under vascular stasis from an 
antecubital vein using a 21G butterfly with a 20 mL syringe 
into 10 mL tubes containing 1: 10 volume of acid citrate 
anticoagulant (2 parts 0.1 mol/L citric acid to 3 parts of 0.1 
mol/L trisodium citrate). Aggregation was induced with ADP 
(2.5 mol/L), and responses were recorded for electrical im-
pedance (Ω) via a computer interface system (Aggrolink, 
Chrono-log, Havertown, Pennsylvania, USA). The NO donor 
sodium nitroprusside (SNP, 10 mol/L) was used to meas-
ure platelet response to NO. Inhibition of aggregation by 
SNP was evaluated as percentage of maximal aggregation in 
the absence of sodium nitroprusside.  
2.4  Platelet thioredoxin-interacting protein  
determination 
Platelet Txnip content was determined as previously re-
ported.[15] Briefly, EDTA-anticoagulated blood was centri-
fuged to obtain platelet rich plasma, which was smeared 
onto untreated slides and fixed using 4% (w/v) paraformal-
dehyde in PBS, then stored at 70C until assayed. Slides 
were blocked using 20% (v/v) goat serum in PBS, followed 
by Txnip detection using rabbit polyclonal anti-human vi-
tamin D3 upregulated protein 1 (VDUP-1) (Invitrogen, 
USA), 1% (w/v) BSA in PBS and incubating overnight at 
2–4C. Secondary detection was performed using FITC- 
conjugated swine anti-rabbit polyclonal IgG (Dako, Den-
mark), as well as primary detection of platelet CD41 using 
RPE-conjugated mouse monoclonal anti-human CD41 
(Dako, Denmark) in PBS. Fluorescence was developed us-
ing ‘fluorescent mounting medium’ (Dako, Denmark) and 
images acquired at 400× using an Axio Scope.A1 micro-
scope with apotome and AxioVision 4.8 software (Carl 
Zeiss, Germany). Images were analysed for densitometric 
fluorescence using AxioVision LE software. The intra-assay 
coefficient of variation (CV) was 8.5% and the inter-assay 
CV was 18.6%. 
2.5  Statistical methods 
Data were analysed by evaluating potential univariate 
followed by multivariate correlates of (a) platelet response 
to NO and (b) platelet response to ADP. Clinical factors 
evaluated were age, sex, LVEF, duration of AF (with “new 
onset” AF defined on the basis of de novo detection), heart 
rate on admission ECG and CHA2DS2VASc score. Analysis 
of covariance was utilized to evaluate the ADP: NO re-
sponse relationship in different patient cohorts. Patient cha-
racteristics were compared by non-paired t-test, Mann- 
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Whitney U test or χ2 test as appropriate. All data for nor-
mally distributed parameters are expressed as mean ± SE 
unless otherwise stated. Skewed data are expressed as me-
dian and interquartile range (IQR). Data were analysed us-
ing the IBM SPSS Statistics 20 and GraphPad Prism 6 
software packages. 
3  Results 
The clinical and pharmacological characteristics of the 
study cohort have been reported previously.[6] Of the total 
cohort, 85.1% were in AF at the time of initial ECG 
recording. A breakdown of clinical parameters assessed 
across gender can be observed in Table 1.  
Females displayed lower incidence of known coronary 
artery disease (CAD), higher LVEF, relatively preserved 
renal function, and higher CHA2DS2VASc scores when 
compared with males.[2] Pharmacotherapy did not differ sig-
nificantly across gender, though a trend towards increased 
statin use in females was noted (Table 2). In particular, there 
was no significant difference between gender as regards 
anti-platelet treatment (e.g., aspirin),[20] or with agents that 
increase platelet NO response, as previously documented 
with statins and angiotensin-converting enzyme (ACE) 
inhibitors.[19,21] 
We previously reported that platelet aggregation is 
increased and NO response decreased in female, compared 
with male AF patients.[6] Currently, we have evaluated the 
relationship between these parameters in a gender-specific 
Table 1.  Clinical characteristics of the study population, by 
gender. 
 Male (n = 45) Female (n = 42) P 
Age, yrs 72 (63, 81) 73 (65, 82) NS
Age ≥ 75 yrs 20 (44.4%) 19 (45.2%) NS
Comorbidities    
Congestive heart failure 3 (6.7%) 4 (9.5%) NS
Hypertension 27 (60.0%) 32 (76.2%) NS
Diabetes mellitus 13 (28.9%) 8 (19.0%) NS
Prior stroke/TIA 5 (11.1%) 4 (9.5%) NS
Known coronary artery disease 20 (44.4%) 9 (21.4%) < 0.05
Clinical presentation    
Admission heart rate, beats/min 85 (72, 134) 96 (70, 136) NS
LVEF, % 58 (49, 60) 62 (58, 68) < 0.01
Plasma creatinine, mol/L 90 (76, 109) 75 (67, 91) < 0.01
Plasma CRP, mg/L 27.0 (11.0, 46.0) 14.0 (5.4, 45.0) NS
CHA2DS2VASc Score 3 (1, 4) 4 (2, 5) < 0.01
New onset AF 11 (24.4%) 11 (26.2%) NS
Data are presented as n (%) or median (IQR). AF: atrial fibrillation; CRP: 
C-reactive protein; IQR: inter quartile range; LVEF: left ventricular ejection 
fraction; NS: not significant; TIA: transient ischaemic attack. 
manner analysis of covariance (ANCOVA, Figure 1), in 
order to determine whether the differing NO response can 
be explained by physiological antagonism.[22] While physi-
ological antagonism was present, female sex represented an 
aggregation-independent basis for impaired platelet NO 
response (P < 0.01).  
We have also previously reported an inverse correlation 
between admission heart rate and platelet response to NO (r 
= 0.331, P < 0.01),[6] while extent of ADP-induced platelet 
aggregation was positively correlated (r = 0.235, P < 0.05). 
Evaluation by ANCOVA (Figure 2) indicated that the heart 
Table 2.  Pharmacotherapy (at time of blood sampling) 
applied in the study population: variation according to gender. 
Antithrombotic therapy Male (n = 45) Female (n = 42) P 
Aspirin 13 (28.9%) 16 (38.1%) NS
Warfarin 24 (53.3%) 26 (61.9%) NS
Rate and/or rhythm control therapy 
Anti-arrhythmics 11 (24.4%) 14 (33.3%) NS
-receptor antagonists 27 (60.0%) 24 (57.1%) NS
Digoxin 14 (31.1%) 15 (35.7%) NS
Calcium channel blockers 9 (20.0%) 13 (31.0%) NS
ACE inhibitors 18 (40.0%) 13 (31.0%) NS
Angiotensin receptor blockers 8 (17.8%) 14 (33.3%) 0.095
Other medications 
Statins 20 (44.4%) 27 (64.3%) 0.064
ACE: angiotensin-converting enzyme; NS: not significant. 
 
Figure 1.  Evaluation of the impact of gender upon the phy-
siological antagonism between pro-aggregatory ADP and anti- 
aggregatory NO responses in AF patients. ANCOVA demon-
strated physiological antagonism: NO response varied inversely 
with extent of aggregation [F(1, 74) = 12.212, P < 0.01]. (1) 
Independent impact of female sex: diminished NO response per 
unit ADP-induced platelet aggregation [F(2, 74) = 8.313, P < 0.01]; 
(2) A non-significant trend [F(1, 74) = 2.244, P = 0.138] towards 
diminution of gender differences (as regards platelet NO response) 
at greater ADP responses. ADP: adenosine diphosphate; AF: atrial 
fibrillation; ANCOVA: analysis of covariance; NO: nitric oxide.  
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rate/aggregation relationships did not vary according to 
duration of AF (similar analysis of the heart rate/NO 
relationships can be found here).[6]  
The potential gender-specificity of the interaction be-
tween heart rate and aggregability parameters was also 
evaluated by ANCOVA (Figure 3). These analyses in-
dicated that for all levels of heart rate, females were 
hyperaggregable compared to males, and that for all levels 
of heart rate, females displayed diminished platelet NO 
response compared to males.  
In our previous report,[6] we speculated that plasma 
‘surges’ in catecholamine levels could foster the develop-
ment of oxidative stress, thus contributing to impaired 
platelet NO response. Txnip is a proinflammatory protein 
that interacts reciprocally with NO signalling (see Chong et 
al.[14] for review): we sought to explore whether platelet 
Txnip expression interacted with new onset AF and/or 
gender in the context of potential catecholamine-mediated 
(i.e., tachycardia) oxidative stress (Figure 4). Neither dura-
tion of AF nor gender significantly correlated with platelet 
Txnip expression. 
 
Figure 2.  Evaluation of the impact of duration of AF on the 
interaction between tachycardia and extent of platelet 
aggregation. ANCOVA confirms that aggregation tends to 
increase (P = 0.071) with tachycardia. However, the relationship 
does not vary significantly according to duration of AF [F(1, 83) = 
0.192, P = 0.662]. As previously reported,[6] there was a significant 
(r = 0.235, P < 0.05) relationship overall between heart rate and 
aggregability. AF: atrial fibrillation; ANCOVA: analysis of cova-
riance. 
 
Figure 3.  ANCOVA evaluation of the impact of gender on the interaction between tachycardia and extent of platelet aggregation 
(A) and platelet response to NO (B). While increasing heart rate was associated with both incremental aggregation (P < 0.05) and 
diminished NO response (P < 0.05), these relationships did not vary significantly according to gender [F(1, 83) = 0.702, P = 0.405; F(1, 73) = 
0.049, P = 0.825, respectively]. ANCOVA: analysis of covariance; NO: nitric oxide. 
4  Discussion 
We have recently demonstrated an association between 
new onset AF and impaired platelet NO response.[6] The 
current data demonstrate that the relationship between heart 
rate and NO response does not vary significantly according 
to whether AF is of recent onset or chronic. Therefore, the 
data are strongly consistent with the concept that the tachy-
cardia commonly associated with new onset AF is closely 
linked with the suppression of platelet NO signaling. One 
potential mechanism to account for the current observations 
would be the precipitation of AF in the presence of in-
creased sympathetic discharge,[23] with associated redox 
stress and NO scavenging. 
We evaluated the relationship between heart rate and 
platelet Txnip content because non-laminar flow may pro-
mote expression of this pro-inflammatory protein.[24,25] 
However, no relationship was found. These data imply 
that impairment of platelet NO response in the presence of 
tachycardia is not mediated via increased Txnip expres-
sion. 
AF in females engenders increased stroke risk when 
compared to males,[26,27] although the precise mechanisms 
for this incremental risk remain uncertain. Furthermore, 
differential stroke incidence in females (compared to males) 
is independent of anticoagulant therapy.[28,29] The specific 
thromboembolic risk represented by gender has even been  
206 Procter NEK, et al. Gender, platelets and AF 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
 
Figure 4.  Platelet Txnip content does not vary significantly 
with heart rate in the entire population evaluation (P = 0.971). 
ANCOVA (data not shown) revealed no heterogeneity of this rela-
tionship according to duration of AF or gender. AF: atrial fibrilla-
tion; ANCOVA: analysis of covariance; Txnip: thioredoxin-inter-
acting protein. 
incorporated into the CHA2DS2VASc stroke risk score, and 
endorsed by current AHA and ESC guidelines.[2,30,31]  
In the current analysis, we postulated that tachycardia 
might contribute to the impaired NO response, and that dif-
ferential biochemical response to tachycardia in females 
might underlie attenuation of NO signaling. Evaluation of 
heart rate was limited to that on admission ECG: this may 
not have been completely representative of heart rate around 
the time of admission, especially in the presence of AF. 
However, ECG data provided an unbiased if limited sample 
of patients’ heart rates. In any event, the tachycardia: NO 
response relationship was gender-independent (Figure 3), 
nor did heart rate vary according to gender (Table 1). The 
potential explanations for impaired NO responses in females 
therefore include both physiological antagonism (that is, a 
consequence of platelet hyperaggregability to ADP),[22] and/ 
or greater susceptibility of ageing females[32–39] to redox 
stress in response to catecholamine release.[10–12] As demon-
strated by the analysis shown in Figure 1, impaired NO re-
sponses in females is actually independent of ADP response. 
In fact, female patients in the current study had a lower 
prevalence of prior coronary artery disease than males, and 
would otherwise be expected to exhibit better-preserved NO 
signaling.[40,41] 
There are some limitations to the present study. Of neces-
sity, the sample size of the cohort and the short follow-up 
period preclude any evaluation and/or conclusions being 
drawn as regards clinical outcomes. Additionally, deter-
mination of heart rate and blood sampling was not always 
concurrent: the substantial impact of heart rate upon platelet 
reactivity remained significant despite this. Lastly, ADP 
was the only agonist used to induce platelet aggregation (as 
opposed to collagen, for example): this was decided upon 
on the basis that ADP-induced platelet aggregation is 
reversible, thus facilitating the evaluation of inhibitory 
signalling pathways (such as those activated by NO).   
In conclusion, while both tachycardia and female gender 
are associated with impaired NO response in AF patients, 
they appear to be entirely independent of one another. The 
potential clinical advantages of reversal of tachycardia in 
terms of restoration of normal platelet homeostasis have not 
been adequately explored to date, but should now be 
evaluated. 
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